Hyundai Bioscience Co Ltd
Hyundai Bioscience Co Ltd operates in the Personal Products industry, focusing on the development, production, and sale of personal care and household products.
Business. Hyundai Bioscience Co Ltd (048410.KQ) is a South Korean company engaged in the personal products industry, operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of personal care items and is headquartered in South Korea. It is primarily listed on the KOSDAQ exchange under the ticker symbol 048410.KQ. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Hyundai Bioscience Co Ltd (048410.KQ) is a South Korean company engaged in the personal products industry, operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of personal care items and is headquartered in South Korea. It is primarily listed on the KOSDAQ exchange under the ticker symbol 048410.KQ. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed in the available data.
Hyundai Bioscience's capital structure is characterized by a low debt-to-equity ratio of 0.16, indicating a conservative leverage position. The company holds significant cash and equivalents of KRW 22,337,858,880, which supports a current ratio of 2.25, suggesting strong short-term liquidity. However, the company's operating cash flow is negative at KRW -17,049,918,860, and free cash flow is also negative at KRW -40,997,020,530, indicating a reliance on external financing or asset sales to fund operations.
Profitability metrics show a return on equity of -0.1998 and a return on assets of -0.1693, both significantly below the industry median for the Personal Products sector. These negative returns suggest the company is underperforming in terms of generating profit from its equity and asset base.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and market-specific risks.
Growth trajectory is negative, with a net income of KRW -22,128,347,690 and an operating income of KRW -18,675,247,510. The company's revenue of KRW 3,517,369,220 is modest, and there are no disclosed plans for significant revenue expansion in the near term.
Risk factors include a low liquidity score and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags, and there are no disclosed plans for share issuance or capital raising in the near term.
Recent events include the latest financial filing, which shows a significant decline in profitability and liquidity. No recent earnings call transcripts or major corporate announcements were identified in the available data.
- Hyundai Bioscience has a conservative capital structure with a low debt-to-equity ratio and strong cash reserves.
- The company is currently unprofitable, with negative returns on equity and assets.
- Revenue is concentrated in a single business segment, with no geographic diversification.
- Growth prospects are limited, with negative net and operating income.
- The company has low liquidity and dilution risk, with no immediate financial distress signals.
- "margin_outlook_rationale": "Margins are expected to remain under pressure due to negative operating and net income trends.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Hyundai Bioscience Co Ltd Market data — financials · 2026-05-26